SESSION TITLE: Asthma Posters
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM
PURPOSE: We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids).
METHODS: Following a run-in phase, patients (12-75 years) inadequately controlled with high-dose inhaled corticosteroids (ICS) and long-acting beta(2)-agonists (LABA) with reduced lung function and a recent history of clinically significant exacerbations were randomized to receive omalizumab or placebo for 24 weeks in a double-blind, parallel-group study.
RESULTS: A total of 51 patients were included in the efficacy analyses. (30 treated with omalizumab), 95% of whom had severe persistent asthma according to the Global Initiative for Asthma (GINA) 2011 update. Omalizumab significantly reduced the rate of asthma exacerbations by 40% (P < 0.0001 vs control) and the rate of total emergency visits by 44% (P < 0.0001 vs control). Omalizumab significantly improved asthma-related quality of life, morning peak expiratory flow and asthma symptom scores.
CONCLUSIONS: In patients with inadequately controlled severe persistent asthma, despite high-dose ICS and LABA therapy, omalizumab significantly reduced the rate of clinically significant asthma exacerbations, severe exacerbations and emergency visits.
CLINICAL IMPLICATIONS: N/A
DISCLOSURE: The following authors have nothing to disclose: Mohamed Zakaria, Sandy Abu-Hussein, Abdallah Abu-Hussein, Mahmoud Ahmed
No Product/Research Disclosure Information